Revolution Medicines' Debut Quarter: $197.6 Million In Rasonque Sales, And A Caution On Early Demand
Executives said two of three patient groups behind the launch quarter are finite, and that five weeks is too short to judge the trend.
Revolution Medicines, a clinical-stage cancer drug developer targeting RAS-driven tumors, booked $197.6 million in net sales of its first approved drug, but executives told analysts on the company's Wednesday earnings call that two of the three patient groups behind it are finite. The quarter covers only about five weeks since the August 26 FDA approval.
Three groups of patients
Anthony Mancini, the company's Chief Global Commercialization Officer, said on the call that demand came from three sources: patients moving over from the expanded access program (free pre-approval supply) to commercial drug, a sizable cohort who had run out of options and were waiting for approval, and newly eligible patients. The first two, he said, are "finite early launch dynamics."
He added that with five weeks of sales it is "too early to draw conclusions about the normalized trajectory." The drug treated more than 5,000 unique commercial patients in the quarter. Mancini said a meaningful share of the early patients are later-stage with lower performance status and may be treated for shorter periods, while newly eligible patients should follow durations closer to the clinical trial.
CFO Jack Anders said the revenue includes initial stocking of the sales channel. The channel ended the quarter with less than two weeks of inventory, and the company expects to hold it near two weeks over the long run. Asked by a TD Cowen analyst to size the stocking in the $198 million, Anders repeated those inventory points rather than giving a dollar amount.
October and the breadth of use
An Evercore ISI analyst asked what October showed about sustainable demand. Mancini said the expanded access program has officially wound down, and that more color without a full quarter "probably isn't going to be a helpful exercise."
Mancini said about 2,700 unique providers prescribed the drug in the quarter, split roughly 60% community practices and 40% academic centers. Claims have been reimbursed across plans covering more than 90% of US pancreatic cancer covered lives, he said, though formal coverage policies are still developing and some claims paid now may not be paid later.
Anders said the gross-to-net discount came in at the low end of the expected 20% to 30% range and should rise within it.
Losses widen as spending climbs
The net loss was $407.5 million, against $305.2 million a year earlier, including a $40.7 million non-cash charge on warrants tied to a stock price increase. Research spending was $417.1 million, up from $262.5 million, and selling and administrative costs were $153.3 million, up from $52.8 million.
The company ended the quarter with $3.7 billion in cash and securities, plus $250 million received in October under its Royalty Pharma funding arrangement. It reiterated 2026 operating expenses of $2.1 billion to $2.2 billion and expects 2027 spending to rise from the current run rate.
A European Commission decision on daraxonrasib, which won a positive opinion from the EMA's drug committee on October 15, remains pending.
The first full quarter of sales, which the company says will give a fuller picture, is the next test of demand once the two finite groups fade.
Sources
- Revolution Medicines GAAP EPS of -$1.90 beats by $0.50, revenue of $197.5M beats by $170.15M (RVMD:NASDAQ) | Seeking Alpha — seekingalpha.com
- Genmab Stock Price Shock Puts 3 Oncology Biotech Names In Focus — Yahoo Finance
- Revolution Medicines Reports Third Quarter 2026 Financial — globenewswire.com
